EcoDrugPlus

Cytochrome P450 3a56-Like

Ensembl ID : ENSFHEG00000006955
Gene Symbol: LOC105937199
2 Cross references
553 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSFHEG00000000261
Gene Symbol: CYP19A1
4 Cross references
246 Possible Orthologues:

Cytochrome P450 Family 46 Subfamily A Member 1

Ensembl ID : ENSFHEG00000005353
Gene Symbol: CYP46A1
3 Cross references
252 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSFHEG00000020294
Gene Symbol: LOC105927936
3 Cross references
215 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSFHEG00000015952
Gene Symbol: LOC105937811
3 Cross references
200 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSFHEG00000009713
Gene Symbol: LOC105935093
3 Cross references
192 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSFHEG00000014868
Gene Symbol: LOC105929695
3 Cross references
188 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSFHEG00000000486
Gene Symbol: DHODH
3 Cross references
173 Possible Orthologues:

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSFHEG00000001338
Gene Symbol: DPYD
3 Cross references
217 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSFHEG00000022871
Gene Symbol: DDR2
3 Cross references
205 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSFHEG00000015840
Gene Symbol: DDR2
3 Cross references
189 Possible Orthologues:

Disintegrin And Metalloproteinase Domain-Containing Protein 17

Ensembl ID : ENSFHEG00000007013
Gene Symbol: LOC105927641
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).